Home > Boards > US Listed > Biotechs > iBio, Inc. (IBIO)

Another hurdle could be shortages of adjuvants, chemicals

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
guay Member Profile
 
Followed By 32
Posts 3,506
Boards Moderated 0
Alias Born 08/04/09
160x600 placeholder
Proxy Statement - Notice of Shareholders Meeting (preliminary) (pre 14a) Edgar (US Regulatory) - 10/23/2020 5:21:56 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 10/22/2020 4:06:23 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 10/16/2020 4:06:25 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 10/16/2020 6:10:52 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 10/16/2020 6:10:08 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 10/16/2020 6:09:10 AM
Initial Statement of Beneficial Ownership (3) Edgar (US Regulatory) - 10/16/2020 6:08:32 AM
Initial Statement of Beneficial Ownership (3) Edgar (US Regulatory) - 10/16/2020 6:07:29 AM
Accomplished Financial Executive, Gary Sender, Joins iBio’s Board of Directors GlobeNewswire Inc. - 10/15/2020 4:05:10 PM
iBio Announces Appointment of Dr. Alexandra Kropotova to Board of Directors GlobeNewswire Inc. - 10/15/2020 7:30:10 AM
iBio Announces Appointment of Dr. Linda Armstrong to Board of Directors GlobeNewswire Inc. - 10/14/2020 4:05:10 PM
Annual Report (10-k) Edgar (US Regulatory) - 10/13/2020 5:19:20 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 10/13/2020 4:28:18 PM
iBio Announces Financial Results for Fiscal Year Ended June 30, 2020 GlobeNewswire Inc. - 10/13/2020 4:05:10 PM
Amended Current Report Filing (8-k/a) Edgar (US Regulatory) - 10/13/2020 7:00:49 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 10/9/2020 4:31:28 PM
Initial Statement of Beneficial Ownership (3) Edgar (US Regulatory) - 10/5/2020 8:32:16 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 10/5/2020 8:01:44 AM
iBio Regains Compliance with NYSE American Continued Listing Standards GlobeNewswire Inc. - 10/5/2020 7:30:10 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 10/2/2020 7:31:01 AM
iBio Enters into Agreement with Safi Biosolutions to Develop Growth Factors and Cytokines Using the FastPharming® System GlobeNewswire Inc. - 10/2/2020 7:00:10 AM
Notification That Annual Report Will Be Submitted Late (nt 10-k) Edgar (US Regulatory) - 9/28/2020 6:07:20 AM
iBio to Advance COVID-19 LicKM-Subunit Vaccine Candidate, IBIO-201 GlobeNewswire Inc. - 9/9/2020 8:45:10 AM
iBio and Planet Biotechnology Enter into Exclusive Worldwide License Agreement for the Development of a COVID-19 Therapeutic GlobeNewswire Inc. - 8/28/2020 7:15:10 AM
Amended Statement of Beneficial Ownership (sc 13d/a) Edgar (US Regulatory) - 8/13/2020 4:55:48 PM
guay   Friday, 08/14/20 07:57:38 AM
Re: Burnz post# 24525
Post # of 25149 
Quote:
Another hurdle could be shortages of adjuvants, chemicals that are sometimes used to boost a vaccine’s immune response, experts said. Novavax, which has agreed to sell the U.S. government at least 100 million doses of its vaccine, reported earlier this month that its shot provoked a stronger immune response when coupled with an adjuvant in early-stage trials.
https://www.politico.com/news/2020/08/12/coronavirus-vaccine-challenges-394444

iBio is investigating an array of adjuvants in combination with iBio’s proprietary lichenase carrier molecule (“LicKMTM”) fused to a coronavirus subunit protein (“IBIO-201”) with the goal of producing a safe and effective vaccine for COVID-19 disease, and especially one for our most vulnerable populations, including the elderly. Ten distinct preclinical study arms for the IBIO-201 antigen-adjuvant combinations have been concluded. These include combinations delivered via intramuscular and intranasal routes, and datasets are under evaluation.




Company Overview
iBio, Inc. (NYSE MKT: IBIO), a leader in the plant-made pharmaceutical field, develops and offers pharmaceutical product applications using its iBio Technology platform.
The iBio Technology platform is a proprietary, transformative technology for the production of biologics including monoclonal antibodies, other therapeutic proteins and vaccines.

#iBio $iBio iBio



Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences